Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.

Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17087-92. doi: 10.1073/pnas.1108745108. Epub 2011 Sep 26.

2.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
3.

The genetics of castration-resistant prostate cancer: what can the germline tell us?

Sharifi N, Dahut WL, Figg WD.

Clin Cancer Res. 2008 Aug 1;14(15):4691-3. doi: 10.1158/1078-0432.CCR-08-0453. Review.

4.

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Review.

PMID:
24979481
5.
6.

Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy.

Culig Z, Klocker H, Bartsch G, Hobisch A.

Am J Pharmacogenomics. 2001;1(4):241-9. Review.

PMID:
12083956
7.

Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.

Sharifi N, Kawasaki BT, Hurt EM, Farrar WL.

Cancer Biol Ther. 2006 Aug;5(8):901-6. Epub 2006 Aug 28. Review.

PMID:
16855379
8.

Overcoming castration resistance in prostate cancer.

Tsao CK, Small AC, Galsky MD, Oh WK.

Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b. Review.

PMID:
22472508
9.

Modeling prostate cancer in mice: limitations and opportunities.

Hensley PJ, Kyprianou N.

J Androl. 2012 Mar-Apr;33(2):133-44. doi: 10.2164/jandrol.111.013987. Epub 2011 Jun 16. Review.

10.

Clonal origin and spread of metastatic prostate cancer.

Van Etten JL, Dehm SM.

Endocr Relat Cancer. 2016 Apr;23(4):R207-17. doi: 10.1530/ERC-16-0049. Epub 2016 Mar 21. Review.

11.

Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.

Huang J, Wang JK, Sun Y.

Curr Opin Urol. 2013 May;23(3):189-93. doi: 10.1097/MOU.0b013e32835e9ef4. Review.

12.

Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.

Mikhaylenko DS, Efremov GD, Strelnikov VV, Zaletaev DV, Alekseev BY.

Curr Genomics. 2017 Jun;18(3):236-243. doi: 10.2174/1389202917666161102095900. Review.

PMID:
28659719
13.

New and emerging factors in tumorigenesis: an overview.

Kim S.

Cancer Manag Res. 2015 Jul 28;7:225-39. doi: 10.2147/CMAR.S47797. eCollection 2015. Review.

14.

Learning about the Importance of Mutation Prevention from Curable Cancers and Benign Tumors.

Wang G, Chen L, Yu B, Zellmer L, Xu N, Liao DJ.

J Cancer. 2016 Jan 28;7(4):436-45. doi: 10.7150/jca.13832. eCollection 2016. Review.

Supplemental Content

Support Center